Key Highlights
- IDEAYA Biosciences unveiled promising Phase 2/3 data for its darovasertib plus crizotinib combination in metastatic uveal melanoma patients
- The combination therapy achieved median progression-free survival of 6.9 months compared to 3.1 months with standard care
- The treatment regimen demonstrated a 58% decrease in the risk of cancer progression
- The combination arm recorded an overall response rate of 37.1% versus only 5.8% in the control group — including 5 complete responses versus zero in the standard care arm
- The company intends to submit a New Drug Application (NDA) to the FDA during the latter half of 2026
Shares of IDEAYA Biosciences (IDYA) experienced a significant premarket rally on Monday following the biotech company’s announcement of encouraging Phase 2/3 clinical trial data for a dual-therapy approach aimed at treating metastatic uveal melanoma — an uncommon and particularly challenging form of cancer affecting the eye.
IDEAYA Biosciences, Inc., IDYA
The clinical study evaluated the combination of darovasertib and crizotinib. Data revealed that this dual-drug regimen more than doubled the median progression-free survival period when compared to conventional standard-of-care treatment approaches.
Participants receiving the combination therapy achieved a median PFS of 6.9 months. In contrast, those on standard treatment protocols reached only 3.1 months. This difference successfully satisfied the study’s primary endpoint.
The dual-therapy approach also delivered a 58% reduction in disease progression risk. This metric is particularly noteworthy for oncology-focused investors.
Impressive Secondary Outcome Metrics
The secondary outcome measures proved equally compelling. The overall response rate for the darovasertib combination registered at 37.1%, while standard care achieved merely 5.8%.
The combination therapy arm produced five patients with complete responses. The standard-care group recorded none.
The median duration of response for patients on the combination regimen reached 6.8 months. Researchers characterized the drug as well-tolerated with a safety profile that is manageable.
Additionally, preliminary data suggested a potential overall survival advantage for the combination treatment compared to standard therapy, although complete data for this measure has not yet matured.
Metastatic uveal melanoma has traditionally presented limited effective therapeutic options. These findings establish darovasertib as a potentially groundbreaking first-in-class treatment for this condition.
Regulatory Submission Scheduled for Second Half of 2026
IDEAYA announced its intention to file a New Drug Application with the FDA during the second half of 2026, utilizing these clinical trial findings as the basis.
This schedule suggests a possible approval determination could arrive in 2027, contingent upon the FDA’s review timeline.
IDYA stock climbed as high as 26.36% during premarket hours, touching $38.60, based on Benzinga Pro data. Some earlier market reports indicated the gain at approximately 15%, with shares trading around $35.
The equity had already been hovering near its 52-week peak of $41.02 prior to Monday’s news. Throughout the past year, IDYA has appreciated approximately 78%.
The broader equity market showed weakness on Monday, with S&P 500 futures declining roughly 0.6% during the period of IDYA’s premarket advance.
IDEAYA has scheduled a complete presentation of trial data at a forthcoming medical conference, with additional details anticipated later in 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
